UPDATE: Qiagen to Buy Cellestis for $355M | GenomeWeb

The story has been updated to include comments from an investment analyst.

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Qiagen announced on Sunday it has agreed to buy Australian biotech firm Cellestis for A$341 million ($355 million) in cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.